Skip to content

Evaluation of Single Session Stereotactic Body Radiotherapy

Phase I/II Evaluation of Single Session Stereotactic Body Radiotherapy for Spinal or Paraspinal Metastases

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00492817
Enrollment
71
Registered
2007-06-27
Start date
2005-10-13
Completion date
2024-11-27
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Neoplasms

Keywords

Spinal Neoplasms, Paraspinal Metastases, Stereotactic Body Radiotherapy, CT-on-Rails, Spinal Cord, SBRT

Brief summary

The goal of this clinical research study is to find out if stereotactic body radiotherapy to the spine using computerized tomography (CT)-on-Rails is safe and effective in the treatment of metastatic spine tumors. Objectives: * Establish the safety and efficacy of using stereotactic body radiotherapy (SBRT) to treat spine and para-spinal tumors in a single session. * Document frequency and severity of pain, symptoms and symptom interference, as well as quality of life before and after treatment. * Document changes in neurological function at defined intervals compared to pre-treatment neurological function.

Detailed description

CT-on-Rails is a system that places the radiation treatment machine in the same room as the CT scanner so that the CT scanner can help deliver radiation more precisely. You will have a MRI of the spine within 1 month before registration on this study. You will also fill out a health survey, a symptom inventory, and a Brief Pain Inventory within 1 week before registration. Each of these surveys should take about 5 minutes to complete. You will have a CT-simulation. The simulation is like a CT scan where a special body frame is used to keep you from moving during scanning and later radiation treatment. However, no radiation is delivered during the simulation. You will be asked questions about your medical history and have a complete neurological exam during your first consultation, before registration. The neurological exam involves testing upper and lower motor strength, sensation to light touch, reflexes, a mental exam, and an evaluation of the way you walk. Radiation treatment will last between 2 and 2 1/2 hours and will be given on 1 day about 1 to 1 1/2 weeks after you had the simulation. You will have a device (similar to plastic wrap) placed around you that will hold you still during the treatment. You will be checked for level of pain and/or discomfort before starting each session of radiation, and you may take pain medications before starting each session. All participants will be treated with radiation therapy that is guided by the CT-on-Rails procedure. On the day of radiation, you will also receive a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment. During treatment, a physician will be monitoring you for any side effects. If you experience severe side effects, radiation treatment will be stopped, and you will be taken off study. After treatment on this study ends, you will have telephone, mail, or facsimile (Fax) follow-ups scheduled at 1, 2, 3, 4, and 8 weeks after radiation. You will be asked questions about any side effects or pain you are experiencing and any other therapies you may have started. You will have follow-up visits scheduled at 3, 6, 9, 12, 18, and 24 months and then every 6 months for the rest of your life. At all follow-up visits, you will be asked questions about your medical history, have a neurological exam, and your neurologic function will be evaluated. Any pain medication you are taking will be noted. You will be asked to have a MRI of the spine at 3, 6, 9, 12,18, and 24 months, then once a year for the rest of your life. You will also be asked to complete 3 questionnaires to evaluate your symptoms, pain, and quality of life at each follow-up visit. Each questionnaire should take around 5 minutes to complete. This is an investigational study. The equipment used in this study are FDA-approved medical devices and are commercially available. However, the way the devices are being used in this study is experimental. Up to 60 patients will take part in this study. All will be enrolled at M. D. Anderson.

Interventions

PROCEDUREStereotactic Body Radiotherapy

On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Radiographically documented spine or paraspinal metastasis demonstrated on spine MRI within 4 weeks of registration 2. Maximum of 2 metastatic sites in the spine to be irradiated in single session 3. Informed consent for irradiation of spinal or para-spinal tumor (s) 4. Diagnosis of cancer including but not limited to lung (non-small cell and small cell), breast, prostate, renal cell, melanoma, gastrointestinal, and germ cell tumors, unknown primary tumors 5. Karnofsky performance status of at least 40 (ie not requiring active hospitalization)

Exclusion criteria

1. Worsening neurological status due to radiographic evidence of spinal cord compression requiring immediate surgical decompression or emergent conventional external radiation therapy. 2. Delay in initiation of radiation treatment would be potentially detrimental to neurological outcome 3. Prior irradiation to current site of interest in the spine 4. Spinal metastasis in the cervical spine are not eligible for treatment 5. Unstable spine requiring surgical stabilization. 6. Sites outside the spine (eg. lung, liver) are not eligible for treatment 7. Patients currently receiving, or who have received chemotherapy within 30 days are not eligible 8. Inability to tolerate lying flat on treatment couch for greater than 30 minutes. 9. Patient with multiple myeloma 10. Patients unable to undergo MRI of the spine 11. Patients with pacemakers

Design outcomes

Primary

MeasureTime frameDescription
Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single SessionSix months after completion of radiation therapyTo measure 6-month complete pain relief, i.e., 6-month pain worst from the BPI being zero
Local Tumor Control Ratelocal tumor control rate, the time frame is up to 48 monthsLocal tumor control rate as measured based on spinal MRI showing absence of progression
Paralysis (Grade 4 Motor Neuropathy)Up to 24 months after radiation therapyEvidence of paralysis (Grade 4 motor neuropathy) casued by radiation myelitis

Countries

United States

Participant flow

Participants by arm

ArmCount
Single Session Stereotactic Body Radiotherapy (SBRT)
On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed. Stereotactic Body Radiotherapy: On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
71
Total71

Baseline characteristics

CharacteristicSingle Session Stereotactic Body Radiotherapy (SBRT)
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
20 Participants
Age, Categorical
Between 18 and 65 years
51 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
50 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
64 Participants
Region of Enrollment
United States
71 participants
Sex: Female, Male
Female
30 Participants
Sex: Female, Male
Male
41 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
63 / 71
other
Total, other adverse events
0 / 71
serious
Total, serious adverse events
7 / 71

Outcome results

Primary

Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session

To measure 6-month complete pain relief, i.e., 6-month pain worst from the BPI being zero

Time frame: Six months after completion of radiation therapy

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Single Session Stereotactic Body Radiotherapy (SBRT)Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session18 Participants
Primary

Local Tumor Control Rate

Local tumor control rate as measured based on spinal MRI showing absence of progression

Time frame: local tumor control rate, the time frame is up to 48 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Single Session Stereotactic Body Radiotherapy (SBRT)Local Tumor Control Rate48 Participants
Primary

Paralysis (Grade 4 Motor Neuropathy)

Evidence of paralysis (Grade 4 motor neuropathy) casued by radiation myelitis

Time frame: Up to 24 months after radiation therapy

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Single Session Stereotactic Body Radiotherapy (SBRT)Paralysis (Grade 4 Motor Neuropathy)0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026